Corcept's CFO Sells Shares via Pre-Set Plan Amid Stock Volatility
Mokari Atabak, Corcept Therapeutics' CFO, sold 40,000 shares worth $3.5 million on July 15, 2026 through a Rule 10b5-1 trading plan established in December 2025. The sale occurred after the stock had risen by 25% over the previous year but followed a prior drop of nearly 50%. Atabak retains ownership of 16,130 shares and holds derivative securities representing more than his direct holdings.
Tickers: $CORT